Duffner P K, Cohen M E, Thomas P R, Sinks L F, Freeman A I
Cancer. 1979 Jan;43(1):41-5. doi: 10.1002/1097-0142(197901)43:1<41::aid-cncr2820430105>3.0.co;2-u.
Five children with recurrent medulloblastomas were treated with Vincristine, BCNU, Methotrexate and Dexamethasone. All five patients responded to therapy. Two of the patients are alive and well 30 and 48 months later; one died of disease 19 months after first recurrence; one developed a further recurrence at 18 months but responded to additional chemotherapy and is alive; and the fifth patient developed a second recurrence after 28 months but has responded to repeat chemotherapy and radiotherapy and is now asymptomatic. These results support the concept that medulloblastomas are sensitive to chemotherapy and suggest that chemotherapy should be considered in cases of recurrent medulloblastomas. In addition, the importance of trials now in progress which employ both adjuvant chemotherapy and radiotherapy in newly diagnosed medulloblastomas is apparent.
五名复发性髓母细胞瘤患儿接受了长春新碱、卡氮芥、甲氨蝶呤和地塞米松治疗。所有五名患者对治疗均有反应。其中两名患者在30个月和48个月后仍存活且状况良好;一名患者在首次复发19个月后死于疾病;一名患者在18个月时出现进一步复发,但对额外化疗有反应且存活;第五名患者在28个月后出现第二次复发,但对重复化疗和放疗有反应,目前无症状。这些结果支持髓母细胞瘤对化疗敏感的概念,并表明复发性髓母细胞瘤病例应考虑化疗。此外,目前正在进行的在新诊断的髓母细胞瘤中采用辅助化疗和放疗的试验的重要性显而易见。